Stage
Acq - P2P | AcquiredValuation
$0000Missing: Penederm's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Penederm's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Penederm News
Apr 9, 2015
COMPANY NEWS; MYLAN LABS AND PENEDERM IN $205 MILLION DEAL Published: June 25, 1998 The generic drug maker Mylan Laboratories Inc. of Pittsburgh agreed yesterday to acquire Penederm Inc. in a deal valued at $205 million. Penederm, of Foster City, Calif., markets patented topically administered prescription products. Under the deal, Penederm shareholders will receive 0.68 share of Mylan common stock for each share of Penederm stock. The deal is valued at about $21.89 a share to Penederm shareholders based on the closing price of Mylan stock on Tuesday. Mylan shares fell 43.75 cents yesterday, to $31.75, while Penederm jumped $4.75, or 30 percent, to $20.50. The transaction is intended to qualify as a tax-free reorganization and is expected to close before the end of the year.
Penederm Frequently Asked Questions (FAQ)
Where is Penederm's headquarters?
Penederm's headquarters is located at 320 Lakeside Drive, Foster City.
What is Penederm's latest funding round?
Penederm's latest funding round is Acq - P2P.
Who are the investors of Penederm?
Investors of Penederm include Mylan and ONSET Ventures.
Who are Penederm's competitors?
Competitors of Penederm include Corium International, Anterios, Edge Therapeutics, Cellnovo, MediQuest Therapeutics and 12 more.
Compare Penederm to Competitors
Travanti offers transdermal delivery of drugs and cosmetic agents utilizing active-patch technology.
Transdermal delivery of drugs and cosmetic agents utilizing active-patch technology. The company was acquired by Teikoku.
Imagine Pharmaceuticals is developing technology to facilitate delivery of drugs to the brain
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. The firm aims to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.
Pantec Biosolutions is a provider of transdermal drug delivery solutions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.